These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25814078)

  • 61. Circulating unconventional T-cell subsets during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
    Konuma T; Kohara C; Watanabe E; Mizukami M; Nagai E; Kato S; Takahashi S; Tojo A
    Eur J Haematol; 2019 Dec; 103(6):623-625. PubMed ID: 31512295
    [No Abstract]   [Full Text] [Related]  

  • 62. Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
    Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Visser O; Cornelissen JJ; Westerweel PE
    Haematologica; 2017 Nov; 102(11):1842-1849. PubMed ID: 28860339
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Maiti A; Cortes J; Ferrajoli A; Estrov Z; Borthakur G; Garcia-Manero G; Jabbour E; Ravandi F; O'Brien S; Kantarjian H
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28278723
    [No Abstract]   [Full Text] [Related]  

  • 64. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
    Gomez-de-León A; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Arguelles GJ
    Expert Rev Hematol; 2017 Sep; 10(9):809-819. PubMed ID: 28742419
    [TBL] [Abstract][Full Text] [Related]  

  • 65. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

  • 66. Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
    Rea D
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):243-247. PubMed ID: 33275744
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pioglitazone with imatinib in CML may reduce residual disease.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e70. PubMed ID: 28089103
    [No Abstract]   [Full Text] [Related]  

  • 68. [Chronic myeloid leukemia – a model disease for targeted therapy].
    Richter J; Stenke L
    Lakartidningen; 2017 Sep; 114():. PubMed ID: 28949401
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Saglio G; Jabbour E
    Leuk Lymphoma; 2018 Jul; 59(7):1523-1538. PubMed ID: 28972424
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The story of tyrosine kinase inhibitors discontinuation in clinical practice.
    Rousselot P
    Leuk Lymphoma; 2018 Dec; 59(12):2782-2791. PubMed ID: 29909726
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.
    Shin H; Ha JE; Zang DY; Kim SH; Do YR; Lee WS; Kim DW; Lee JI
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e521-e529. PubMed ID: 33632667
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chronic myeloid leukemia: room for improvement?
    Baccarani M; Pane F; Rosti G; Russo D; Saglio G
    Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
    [No Abstract]   [Full Text] [Related]  

  • 73. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
    Shimizu A; Hattori M; Takeuchi Y; Ishikawa O
    J Dermatol; 2016 Sep; 43(9):1100-1. PubMed ID: 27028020
    [No Abstract]   [Full Text] [Related]  

  • 74. Mechanisms of drug resistance in kinases.
    Barouch-Bentov R; Sauer K
    Expert Opin Investig Drugs; 2011 Feb; 20(2):153-208. PubMed ID: 21235428
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Present results and future perspectives in optimizing chronic myeloid leukemia therapy.
    Carella AM; Saglio G; Mahon XF; Mauro MJ
    Haematologica; 2018 Jun; 103(6):928-930. PubMed ID: 29866888
    [No Abstract]   [Full Text] [Related]  

  • 76. An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.
    Kunbaz A; Eskazan AE
    Expert Rev Hematol; 2019 Jul; 12(7):477-480. PubMed ID: 31166812
    [No Abstract]   [Full Text] [Related]  

  • 77. Challenges in management of older patients with chronic myeloid leukemia.
    Stempel JM; Shallis RM; Wong R; Podoltsev NA
    Leuk Lymphoma; 2024 Sep; 65(9):1219-1232. PubMed ID: 38652861
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
    Ottmann O; Saglio G; Apperley JF; Arthur C; Bullorsky E; Charbonnier A; Dipersio JF; Kantarjian H; Khoury HJ; Kim DW; Healey D; Strauss L; Cortes JE
    Blood Cancer J; 2018 Sep; 8(9):88. PubMed ID: 30190469
    [No Abstract]   [Full Text] [Related]  

  • 80. Is There a Role for Dose Modification of TKI Therapy in CML?
    Copland M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):337-345. PubMed ID: 31197525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.